If you are looking to buy high-quality companies, these out-of-favor drugmakers should be on your short list in the healthcare sector. And they both happen to look undervalued right now, opening up an opportunity for buy-and-hold investors.
Although they both face a similar headwind today, they have demonstrated that they can effectively address the challenges they encounter. Here’s a look at each one of these drug stocks and their lofty dividend yields.
This post originally appeared at The Motley Fool.